Degenerative Joint Articles & Analysis: Older
3 news found
BRIM Biotechnology, Inc. (“BRIM”) a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”) the world’s leading, ophthalmic research organization, for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). BRIM ...
Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks Israel-based Moebius Medical today announced that the first patient has been dosed in its Phase IIb clinical trial of MM-II, a novel candidate for the treatment of pain ...
Treatment leverages proprietary liposomes and first-in-class mechanism-of-action to achieve significant, sustainable pain relief Phase IIb study expected to begin enrolling by year-end with initial top-line data anticipated in mid-2022 Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Investigational New Drug (IND) application to ...